Heka Bio Co., Ltd.
Terrapeutics Pharma and HekaBio K.K. partner to bring innovative drug discovery platform to Japan
……
[Reference materials]
This press release is a Japanese translation of the English version of the press release issued on June 19, 2024 (local time) by Terrapeutics Pharma (Headquarters: Israel) and HekaBio Co., Ltd. (Headquarters: Chuo-ku, Tokyo). Official information is based on the English version of the press release, and the English version takes precedence for content and interpretation.
Click here for the English press release — https://shorturl.at/9MZrm
[Image: https://prtimes.jp/i/33569/13/resize/d33569-13-c556e75eea059ddbfcc2-0.png&s3=33569-13-5ef1c8756b78362a5c9201ef880ea22b-722×133.png ]
[Jerusalem, Tokyo – June 19, 2024]
Terrapeutics Pharma Ltd. (“Therapeutics”), a pioneering drug discovery company specializing in identifying new drugs from soil-borne bacteria, and Japan-based in-licensing and commercialization of innovative medical technologies. HekaBio Co., Ltd. (HekaBio), a technology platform, today announced the conclusion of a strategic partnership.
Therapeutics is revolutionizing drug development with innovative drug discovery methods that target the soil microbiome with a focus on specific human drug targets. This innovative method allows soil bacteria to harness their ‘natural intelligence’ to produce highly specific small molecule inhibitors.
By identifying these microorganisms and their biosynthetic clusters, therapeutics is providing an astonishing 1,000-fold increase in access compared to traditional methods, revealing hidden molecules in nature. Through this partnership, we aim to introduce Therapeutics’ innovative drug discovery platform to the Japanese market. In particular, the aim is to promote joint research with pharmaceutical companies to discover new therapeutic drugs targeting diseases that have been considered “undruggable” and difficult to develop.
Therapeutics’ platform provides Japanese pharmaceutical companies with rapid access to drug target-specific natural molecules (DT-SNMs) to rapidly develop naturally-derived inhibitors against the most difficult drug targets. allows for identification. These naturally derived solutions have the potential to revolutionize drug discovery, either as direct therapeutics or as inspiration for biomimetics. As part of this partnership, HekaBio CEO Robert Clare will join Therapeutics’ advisory board. Claire will leverage her extensive experience and deep knowledge of the Japanese biopharmaceutical field to support Therapeutics’ vision in Japan. Leveraging HekaBio’s extensive network and expertise in the Japanese market, we will focus on expanding Therapeutics’ innovative drug discovery platform into Japan.
“We are thrilled to partner with HekaBio and introduce our
groundbreaking drug discovery platform to Japan,” said Eddie Sadan, CEO and co-founder of Therapeutics. “We welcome Rob to our advisory board. This marks an important milestone for Therapeutics. His leadership and expertise will foster collaboration with Japanese pharmaceutical companies to discover new therapeutics from soil bacteria and address unmet medical needs. is essential.”
Rob Clare, CEO of HekaBio, said: “This partnership allows us to bring innovative tools to the Japanese pharmaceutical industry and also embodies our mission to accelerate access to global innovation. We look forward to working closely with Therapeutics to unlock new therapeutic possibilities and contribute to the advancement of drug discovery.”
About HekaBio
HekaBio is a Japan-based platform that handles the licensing and commercialization of medical devices and therapeutic drugs. With a mission of collaboration, creativity and commitment, HekaBio aims to empower patients through rapid access to global healthcare innovation. Website: https://www.heka.bio
LinkedIn: https://www.linkedin.com/company/hekabio/
About Therapeutics Pharma
Therapeutics is a drug discovery company reviving the lost art of discovering innovative therapeutic solutions from soil microorganisms. This ground-breaking discovery technology combines synthetic biology, sequencing tools and computational biology to unlock the full potential of soil and create new solutions that can address diseases that have traditionally been considered “hard to target.” Enables the discovery of low molecular weight compounds.
Website: https://www.terrapeuticspharma.com
LinkedIn: https://www.linkedin.com/company/terrapeutics-pharma/
This article has been partially generated with the assistance of AI.